Affordable Access

Access to the full text

The therapeutic effects of microRNAs in preclinical studies of acute kidney injury: a systematic review protocol

  • Zankar, Sarah1
  • Rodriguez, Rosendo A.1
  • Vinas, Jose Luis2
  • Burns, Kevin D.2
  • 1 The Ottawa Hospital and University of Ottawa, Department of Medicine, 501 Smyth Road, Ottawa, Ontario, K1H 8L6, Canada , Ottawa (Canada)
  • 2 Ottawa Hospital Research Institute, University of Ottawa, Division of Nephrology, Department of Medicine, Kidney Research Centre, 1967 Riverside Drive, Rm. 535, Ottawa, Ontario, K1H 7W9, Canada , Ottawa (Canada)
Published Article
Systematic Reviews
BioMed Central
Publication Date
Oct 10, 2019
DOI: 10.1186/s13643-019-1150-1
Springer Nature


BackgroundAcute kidney injury (AKI) causes significant morbidity and mortality in humans, and there are currently no effective treatments to enhance renal recovery. MicroRNAs (miRNAs) are short chain nucleotides that regulate protein expression and have been implicated in the pathogenesis of AKI. Recently, preclinical studies in vivo have uncovered a therapeutic role for administration of specific miRNAs in AKI. However, the overall benefits of this strategy in preclinical studies have not been systematically reviewed, and the potential for translation to human studies is unclear.AimThe primary aim is to conduct a systematic review of the therapeutic properties of miRNAs in preclinical studies of AKI. The secondary aim is to determine potential adverse effects of miRNA administration in these studies.MethodsA comprehensive search strategy will identify relevant studies in AKI in vivo models, using the MEDLINE, EMBASE, OVID, PUBMED, and Web of Science databases. The search strategy will include terms for mammalian (non-human) AKI models, including injury related to ischemia/reperfusion, nephrotoxicity, sepsis, contrast agents, cardio-pulmonary bypass, and hemorrhagic shock. Interventions will be defined as direct administration of exogenous miRNAs or antagonists of miRNAs, as well as maneuvers that alter expression of miRNAs that are mechanistically linked to AKI outcomes. The primary outcomes will be indices of kidney function and structure, and there will be no restriction on comparator interventions. Two independent investigators will initially screen abstracts, and selected articles that meet eligibility criteria will be reviewed for data abstraction and analysis. The SYRCLE RoB tool for animal studies will determine risk of bias, and meta-analysis will be performed as appropriate. The GRADE methodology will assess the quality of evidence.DiscussionThe administration of selective miRNA mimics or antagonists exerts beneficial effects in mammalian models of AKI, although multiple obstacles must be addressed prior to translation to human clinical trials. The proposed systematic review will document key miRNA candidates, and determine effect size estimates and sources of outcome bias. The review will also identify gaps in knowledge and guide future directions in AKI research.Systematic review registrationPROSPERO CRD42019128854

Report this publication


Seen <100 times